Biogen shares fell after a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease the company is developing with Eisai https://t.co/kcKEfuJNBN— Bloomberg (@business) November 28, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


